Q BioMed Inc : SeeThruEquity Issues Update on Q BioMed Inc. (QBIO)

SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Q BioMed Inc. (OTCQB:QBIO). Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company focused on identifying, acquiring and licensing attractive biomedical assets from small private companies and academia …

SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Q BioMed Inc. (OTCQB:QBIO).
Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company focused on identifying, acquiring and licensing attractive biomedical assets from small private companies and academia lacking the resources to bring programs to market on their own. QBIO seeks to add value to its investments by providing strategic capital, industry resources, and experience in order to accelerate the development and commercialization of life science assets. QBIO is led by an experienced management team with a meaningful stake in the company, which sees several potential catalysts over the next year, including the continued advancement of its initial clinical candidate, MAN-01 for glaucoma, imminent commercialization of Strontium Chloride (“SR89”), an FDA-approved generic drug indicated for palliative care for patients suffering from metastatic cancer that has spread to the bone, and the recently acquired license for QBM-001 a drug candidate for a rare pediatric disorder resulting in infants becoming nonverbal or minimally verbal later in life, while also presenting on the autistic spectrum. QBIO also just announced that it has licensed plant based small molecule, Uttroside B, a new chemotherapeutic drug program for treatment of liver cancer from the Oklahoma Medical Research Foundation.
SR89 tracking ahead of schedule, revenue ready
QBIO announced that it initiated production of Strontium Chloride (“SR89”), which is slated to be its first commercial product. Management indicated that SR89 is tracking ahead of schedule, a launch planned in this calendar year. SR89 is an FDA-approved radiopharmaceutical agent indicated palliative care for patients suffering from metastatic bone cancer, an extremely painful condition that is thought to occur in approximately 70% of patients with advanced breast and prostate cancer. This represents a large initial opportunity, given that each year there are approximately 100,000 new cases of bone metastases in patients with breast and lung cancer in the U.S. alone. QBIO had initially estimated that it could achieve more than $1mn in sales in its first year of commercialization with an intermediate goal (3-5 years) of generating more than $10mn per year in sales. We note that SR89 appears particularly attractive as an approved pain treatment that can be used as an alternative or in combination with opiates and cancer therapeutic drugs and is an indication that could be expanded into a larger therapeutic market quite easily, a move that could generate substantially greater revenues.
New license of QBM-001 expands pipeline
QBIO also followed through on its commitment to expand its asset portfolio with an in-licensing deal for QBM-001 from private biotech firm ASDERA. Formerly named ASD-002, QBM-001 is being developed as a treatment to prevent a non-verbal disorder related to autism in toddlers, and, if approved, would be the first drug on the market for this indication, according to the company. For each child that becomes nonverbal or minimally verbal, there is a $10mn socio-economic cost spanning the rest of the child’s life. Not factored into that figure is the pain and burden it places on parents and families. Each year there are 15,000-18,000 more children that will be born in the US, who will become non- or minimally verbal. QBIO estimates that this could represent a billion-dollar opportunity and indicated that they will pursue a 505(b)2 regulatory pathway with a single Phase 2/3 pivotal trial, which, if successful, management estimates would have the drug ready for market in less than 2 years.
Please review important disclosures on our website at www.seethruequity.com.
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high-quality research on underfollowed small cap and micro cap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
Click here to connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.

Source: www.4-traders.com

Featured
Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. has been approved for listing. Listing and disclosure documents will be available at on the trading date. Love Pharma Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, ...

Le 29 septembreSeptember 2021) Love Pharma Inc., the issuer resulting from a Fundamental Change of Glenbriar Technologies Inc. (GTI.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

read more Show less

A breakdown of everything to know about how to invest in life science — from biotech and pharmaceuticals to medical devices and genetics.

The overarching term “life science” refers to the study of living organisms and life processes. Given the sector’s broad reach, many investors aren’t sure exactly how to invest in life science. 

To start, it’s important to understand that the industry encompasses the fields of biotechnology, pharmaceuticals, medical devices and genetics, to name just a few. Companies within each subsector are involved in researching and developing innovative products, advancing technology and striving towards drug or device commercialization by way of clinical trials and patent applications.

read more Show less
Sixth Wave Innovations Inc. is pleased to announce the finalization of a commercial system design for Affinity™ cannabis purification technology. SIXW is contracted to deliver three units to Oregon-based producer Green Envy Extracts after successful field trials beginning in the fall of 2021.The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with ...

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to announce the finalization of a commercial system design for Affinity™ cannabis purification technology. SIXW is contracted to deliver three units to Oregon-based producer Green Envy Extracts (the "Customer") after successful field trials beginning in the fall of 2021.

The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with the highest possible THC/cannabinoid purity with greater consistency that consumers demand. Affinity™ machines will use Sixth Wave's breakthrough nanotechnology to significantly increase yields for producers by reducing the amount of cannabis lost through traditional methods in faster times with lower costs.

read more Show less
text saying "top stories this week"

Catch up and get informed with this week's content highlights from Charlotte McLeod, our editorial director.

Top Stories This Week: Powell Gets Fed Nomination, Using Gold in a Market Correction youtu.be

We're back after a break last week with quite a bit to cover in the gold space.

After running up past the US$1,860 per ounce mark midway through November, the yellow metal has taken a tumble. At the time of this writing on Friday (November 26) afternoon, it was sitting just under US$1,790.

Gold's losses this week have been attributed to elements like a stronger US dollar and better Treasury yields, although Jerome Powell's US Federal Reserve chair renomination has pulled other factors into play — some market watchers believe he may move to taper and raise interest rates faster than anticipated.


If the Fed follows its previously laid out timeline for tapering, it will wrap up in mid-2022; the central bank has said it won't raise rates until after that. It has also emphasized that its roadmap may change if necessary.

Looking at the larger picture for gold, I heard recently from Nick Barisheff of BMG Group, who believes the stock market is due for a major correction.

"The market is due for a major correction. What will cause it and when it will happen is anybody's guess — it could be tomorrow, it could be six months from now" — Nick Barisheff, BMG Group

It's impossible to know when this correction will happen, but Nick emphasized the importance of acting before it's too late. He pointed out that investors are typically slow to get out of the market once a crash actually begins — they wait for a turnaround, and by the time it's clear there won't be one, they've experienced big losses.

In his opinion, the solution is to get out of the stock market early and transfer money into gold.

Here's how Nick explained it:

"Instead of taking your money off the table and going into cash … you go to gold (because cash is devaluing daily). Gold will at least hold its own and probably appreciate … so by sitting it out in gold you can wait until the market finishes correcting and then buy back in" — Nick Barisheff, BMG Group

With gold's future in mind, we asked our Twitter followers this week what price they think the metal will be at the end of 2021. By the time the poll closed, most respondents had voted for the US$1,800 to US$1,900 range.

We'll be asking another question on Twitter next week, so make sure to follow us @INN_Resource or follow me @Charlotte_McL to share your thoughts.

Finally, in the cannabis space, INN's Bryan Mc Govern spoke with Dan Ahrens of AdvisorShares to get his thoughts on 2021 trends and what's ahead in 2022.

Dan was candid, and said if he had to choose one word to describe the cannabis market in 2021, it would be "painful." Like many others, he's been disappointed in the industry's performance — while positivity initially ran high due to excitement about potential federal changes in the US, ultimately progress has been slow.

"Cannabis started with a big run-up in January and February ... and things dragged from there" — Dan Ahrens, AdvisorShares

Still, Dan has hope for 2022 and said it will be a "huge year" for cannabis. He believes US reforms will come sooner rather than later, and in his opinion those widely anticipated changes will bring a wave of M&A activity.

Specifically, he expects to see alcohol, tobacco and other consumer packaged goods companies making deals with cannabis players, not just cannabis entities doing transactions with each other.

"Those big alcohol companies, tobacco companies, other consumer packaged goods product companies — they're waiting. They're waiting on the US" — Dan Ahrens, AdvisorShares

Want more YouTube content? Check out our YouTube playlist At Home With INN, which features interviews with experts in the resource space. If there's someone you'd like to see us interview, please send an email to cmcleod@investingnews.com.

And don't forget to follow us @INN_Resource for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

cannabis plant layered with German flag graphic
Dmytro Tyshchenko / Shutterstock

Catch up on some of the biggest news of the week for the cannabis investment world.

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.


Coalition of parties promises forward-looking cannabis policy

Germany, a country with comprehensive and elaborate medicinal rules for cannabis, is in a time of transition as a new government is set to begin to take over after 16 years of Angela Merkel.

Olaf Scholz, the proposed next chancellor of Germany, leads a three party coalition that will become the country's governing body. As part of its promises, talk of adult-use cannabis regulation has now gained even more momentum. A report from MJBizDaily quotes a German policy document that shows the coalition's stance:

"We are introducing the controlled distribution of cannabis to adults for consumption purposes in licensed shops. This controls the quality, prevents the transfer of contaminated substances and guarantees the protection of minors."

However, despite the promise and excitement, it remains to be seen how these ideas will be applied since no formal regulations have been drafted or approved yet.

Canadian cannabis retailer partners with popular delivery app

Tokyo Smoke, a cannabis retail operator in Canada owned by Canopy Growth (NASDAQ:CGC,TSX:WEED), announced a collaboration agreement with Uber Canada (NYSE:UBER) whereby cannabis consumers will be able to use the Uber Eats app to order products before they visit stores.

While the app won't let consumers get cannabis delivered to them, this new method opens the doors to more dynamic ways of buying cannabis.

"As a market leader in innovation and a platform used by so many Canadians, we believe this is the ideal next offering that can be done safely and conveniently on the Uber Eats app," Mark Hillard, vice president of operations with Tokyo Smoke, said in a press release.

A report from the Canadian Press indicates Ontario is considering allowing dispensaries to have delivery and pickup options made available to consumers permanently. The province allowed some of these purchasing options at the outset of the COVID-19 pandemic, but then removed them.

Lola Kassim, general manager of Uber Eats Canada, said this new end-to-end experience will provide consumers with responsible access to legal cannabis products.

Cannabis company news

  • Organigram Holdings (NASDAQ:OGI,TSX:OGI) issued financial results for its Q4 2021 period. In its report, the company notes a net loss of C$26 million despite a 22 percent uptick in net revenue to C$24.9 million. Beena Goldenberg, the newly appointed CEO of the firm, is encouraged by the market share position earned by the company, which said it became the fourth biggest producer in Canada during the reporting period.
  • Halo Collective (NEO:HALO,OTCQB:HCANF) confirmed the decision for Akanda, its spinoff company focused on international cannabis opportunities, to begin trading on a US exchange. "The number of shares to be offered and the price range for the proposed offering have not yet been determined," the company told investors in a press release.
  • High Tide (NASDAQ:HITI,TSXV:HITI) announced the acquisition of 80 percent of NuLeaf Naturals, a CBD product wellness developer, for an estimated US$31.24 million. The deal includes a three year option clause for High Tide to complete a total acquisition. "As international markets open up and as export regulations evolve, NuLeaf's cGMP-certified facility positions us to take advantage of the global CBD business opportunity," Raj Grover, president and CEO of High Tide, said.
  • Humble & Fume (CSE:HMBL,OTC Pink:HUMBF) released the financial report for its first 2022 fiscal quarter to shareholders and the market. "As the legal cannabis market in North America continues to mature, Humble remains agile and focused on providing a leading solution for brands to scale quickly and retailers to focus on their customers," Joel Toguri, CEO of Humble, said.

Don't forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

MARKETS

Markets
TSX21125.90-487.28
TSXV944.05-31.53
DOW34899.34-905.04
S&P 5004594.62-106.84
NASD15491.66-353.57
ASX7279.30-128.00

COMMODITIES

Commodities
Gold1792.60+0.99
Silver23.13+0.02
Copper4.29-0.18
Palladium1751.49+10.50
Platinum955.50+2.50
Oil68.17-10.22
Heating Oil2.09-0.29
Natural Gas5.49+0.43

DOWNLOAD FREE REPORTS